BRIEF-Gilead receives approval in Canada for Vosevi for re-treatment of certain patients with chronic hep c virus infection

* Gilead receives approval in Canada for Vosevi™ (sofosbuvir/velpatasvir/voxilaprevir) for re-treatment of certain patients with chronic hepatitis c virus (HCV) infection Source text for Eikon: Further company coverage:
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.